Tag Archives: tzield

Sanofi Acquires Provention Bio; Ozempic Takes Stage at Oscars

Two CVRM-related news items have been observed: Sanofi and Provention have entered a $2.9B acquisition deal (press release); and Ozempic takes center stage at the 2022 Oscar awards show (view article). Below, FENIX provides highlights and insights from the news items, including thoughts on how the Provention Bio acquisition fits into Sanofi’s diabetes strategy.

This content is for Read Less members only.
Already a member? Log in here

Abbott Q4 ’22 Earnings; Tidepool Loop Receives FDA Clearance; Lilly to Expand Incretin Manufacturing Capacity; Novo Receives Marketing Practices Complaint; AGC Biologics to Manufacture Tzield; Nemaura Reports Positive Miboko Data; J&J Q4 ’22 Earnings; and Embecta Opens New Headquarters

A series of cardiometabolic-related news items were observed from Tidepool, Lilly, Novo, Embecta, AGC Biologics, and Nemaura. Additionally, Abbott and J&J hosted Q4 ’22 earnings calls. Below, FENIX provides highlights and insights into the respective news items including commentary on why the claims against Novo’s marketing practices seem unfounded.

This content is for Read Less members only.
Already a member? Log in here

Tzield (teplizumab) Label and Website Analysis

FDA recently approved Provention Bio’s teplizumab, branded as Tzield, to delay the onset of Stage 3 T1DM in adult and pediatric patients aged 8 years and older with Stage 2 T1DM (previous FENIX insight). Additionally, Provention hosted an investor call on Friday, November 18, 2022, to discuss the approved Tzield label, pricing, and commercialization plans (webcast). Below FENIX has conducted a Tzield label and website analysis, including highlights and insights from the investor call (label; previous FENIX insight).

This content is for members only.
Already a member? Log in here